Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Linda Jeeva Kumari Henry

Linda Jeeva Kumari Henry

Anna University, India

Title: Nanomedicine and Biomedical Applications

Biography

Biography: Linda Jeeva Kumari Henry

Abstract

Nanoparticle-based drug delivery systems are developed to target alveolar macrophages associated with pulmonary inflammation. Allergic asthma is a chronic inflammatory lung disease characterized by airway hyperresponsiveness, airway inflammation and goblet cell hyperplasia to inhaled allergens and nonspecific stimuli. Peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear hormone receptor is expressed in the structural and inflammatory cells of the lungs that regulates inflammatory responses in asthma pathophysiology. Galangin, a flavonoid present in Alpinia officinarum is a PPARγ agonist proven to possess anti-asthmatic property. Despite the potent therapeutic efficacy of galangin, poor aqueous solubility limits its pharmacological activity. Polymeric nanoparticles are biocompatible, safe and stable with sustained release property which are required for better therapeutic applications. Hence, nanoparticle-based approach was adopted to enhance the therapeutic efficacy of galangin, forming the rationale of the study. Activation of PPARγ may also occur by ligand-independent transcriptional activity, and conversely, the ligand may follow PPARγ-independent pathway. Therefore, our hypothesis is that galangin loaded polymeric nanoparticles (G-NPs) could enhance the anti-asthmatic effect of encapsulated galangin over free galangin via PPARγ-dependent pathway. In this study, G-NPs were prepared and characterized. In vitro drug release and hemocompatibility studies were performed. In vivo anti-asthmatic studies in ovalbumin-induced murine model were performed, wherein, G-NPs significantly ameliorated the pro-inflammatory mediators. Expression (mRNA and protein) analyses confirm the mechanistic action of PPARγ. Taken together, our findings communicate that nanoencapsulated compound exhibited better anti-asthmatic activity over free compound by suppressing the pro-inflammatory mediators via PPARγ-dependent pathway, thereby implying PPARγ as a therapeutic target for asthma.